Ligand Pharmaceuticals (LGND) Cost of Revenue (2011 - 2026)
Ligand Pharmaceuticals (LGND) posted Cost of Revenue of $3.3 million for Q1 2026, up 9.39% sequentially from $3.0 million in Q4 2025, and down 32.5% YoY from $4.8 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Cost of Revenue (2011 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Cost of Revenue for 16 years, with the latest figure at $3.3 million in Q1 2026.
- Quarterly Cost of Revenue fell 32.5% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (down 0.52% YoY) and the FY2025 annual result came in at $14.5 million, up 31.38% from the prior year.
- Cost of Revenue advanced to $3.3 million in Q1 2026 per LGND's latest filing, from $3.0 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $21.6 million in Q4 2022 and troughed at $1.6 million in Q4 2023.
- A 5-year average of $5.4 million and a median of $3.3 million in 2026 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 80.36% in 2022, then sank 92.41% in 2023.
- Over 5 years, Cost of Revenue stood at $21.6 million in 2022, then tumbled by 92.41% to $1.6 million in 2023, then surged by 72.88% to $2.8 million in 2024, then grew by 5.46% to $3.0 million in 2025, then climbed by 9.39% to $3.3 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $3.3 million, $3.0 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.21 Mn |
| Jun 30, 2026 | 3.21 Mn |
| Mar 31, 2026 | 3.27 Mn |
| Mar 31, 2026 | 3.27 Mn |
| Dec 31, 2025 | 2.99 Mn |
| Dec 31, 2025 | 2.99 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 2.91 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |